

July 14, 2014

Matrix, Company Name 3 - D Ltd. Address 3-2-4, Kojimachi, Chiyoda, Tokyo President Kentaro Takamura Code Number 7777 Contact Director Tomoyuki Arai \mathbf{T} +81 3 (3511)3440 \mathbf{E} \mathbf{L}

Absorbable Hemostat "PuraStat®" Commencement of clinical use in the European Union

The 3-D Matrix group has been working towards starting clinical use of absorbable hemostat "PuraStat®" since obtaining CE marking for the product on January 14, 2014. The company hereby announces that on July 1, 2014, clinical use of the product has commenced at the St. John of God Hospital in Austria.

St John of God Hospital, Department of Surgery, Bernhard DAUSER, M.D. conducted the clinical use to control bleeding during a surgical procedure. St John of God Hospital is a flagship hospital conducting more than 4,000 surgery cases annually.

With the commencement of clinical use, the company aims to further promote clinical use of PuraStat® in our core European markets, and expand the distribution of the product through an exclusive agreement with a marketing partner.

This announcement does not influence the earning forecast of the company at this moment.